Shu-Yin (Tina) Yu
Tina is a U.S. lawyer based in London. Tina has been a member of Ropes & Gray’s Litigation and Enforcement team since 2012, and was originally based in Ropes & Gray’s Hong Kong office. She has significant experience in handling cross-border matters relating to anti-corruption and related misconduct, including government-initiated and internal investigations as well as risk assessments. Tina’s work has covered jurisdictions spanning Asia, the Middle East and Europe. Tina has represented clients in the life sciences and technology industries, including companies undergoing government investigations as well as companies subject to deferred prosecution agreements and government monitorships.
Tina was recently seconded to the Regulatory Compliance team of the Legal Department of one of the world’s leading integrated oil and gas companies, where she advised on the compliance risk of various projects.
Furthermore, Tina advises private equity and other investor clients on risk-based due diligence of potential targets and portfolio companies. She has also assisted in the review and update of a sovereign wealth fund’s anti-corruption program.
Prior to joining Ropes & Gray, Tina was an associate at an international law firm, where she was involved in numerous high profile corporate transactions.
- Conducted numerous internal investigations relating to the Foreign Corrupt Practices Act (“FCPA”) on behalf of several multinational life sciences companies; investigations included those in China, Japan, Malaysia, Taiwan, Thailand, India and Saudi Arabia. Also conducted internal investigations for a leading private equity company and a multinational information technology company in China.
- Represented a multinational medical device company in a government appointed compliance monitorship, with a focus on its operations in Japan, India and Western Europe.
- Represented top executives from a Chinese telecommunications company in an export controls investigation by the Department of Justice, Department of Commerce and Department of Treasury.
- Represented a multinational life sciences company in relation to inquiries from the World Bank.
- Conducted anti-corruption, sanctions and anti-money laundering risk assessments and due diligence for top private equity firms relating to portfolio companies and proposed investments in various jurisdictions.
- Reviewed, developed and implemented anti-corruption compliance policies for various clients including multinational life sciences companies, private equity companies, private equity portfolio companies and a sovereign wealth fund. Also conducted compliance trainings for various private equity portfolio companies.
- Co-author, “Distributors Expose Health, Life Science Companies To FCPA Risks,” Law360 (August 14, 2018)
- Co-author, “Tips for an Effective Anticorruption Monitoring Program,” Corporate Counsel (September 5, 2014)